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ABSTRACT 
 
Ricker, Ellen Marie.  M.S., Department of Neuroscience, Cell Biology, and Physiology, 
Wright State University, 2015.  The inhibitory effects of opioids on voltage-gated 
calcium influx in neonatal rat carotid body type I cells. 
 
 
 
 It is known that opioids inhibit the hypoxic ventilatory response, but little is 
known about the mechanisms that underpin this. This study’s objectives were to 
examine which opioid receptors are located on the oxygen-sensing carotid body 
type I cells and determine whether selective agonists inhibit cellular excitability. 
 Immunocytochemistry revealed the presence of μ and κ opioid receptors on 
type I cells. The μ-selective agonist DAMGO (10μM) and the κ-selective agonist  
U50-488 (10μM) significantly (p<0.0025 and p<0.0095 respectively, unpaired 
student’s t-test) inhibited high K+ induced rises in intracellular Ca2+ compared with 
controls. After a three-hour incubation with pertussis toxin, a Gi protein-coupled 
inhibitor, DAMGO and U50-488 (10μM) has no significant effect on the responses to 
K+. 
 These results indicate that opioids acting at μ and κ receptors inhibit voltage-
gated Ca2+ influx in carotid body type I cells. This mechanism may explain, in part, 
why opioids inhibit the hypoxic ventilatory response.  
  This work appeared in abstract form at the Ohio Physiological Society meeting 2013. 
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THE CAROTID BODY 
 The carotid bodies (CB) are sensory organs that sit bilaterally at the 
bifurcation of the common carotid arteries in the neck (Figure 1A). These small 
organs are the body’s primary peripheral chemoreceptors meaning they modulate 
breathing in response to changes in arterial gases and pH. In response to hypoxia, 
hypercapnia, and acidosis, the carotid bodies release neurotransmitters that can 
culminate in hyperventilation to restore blood gas homeostasis. 
 
Microanatomy of the Carotid Body 
 There are two main types of cells that make up the CB: type I cells and type II 
cells (Figure 1B). Forming the majority of the organ, type I, or glomus cells, are the 
excitable cells responsible for forming synapses with afferents from the carotid 
sinus nerve (CSN). Type I cells are distinguished by their large, dense-core vesicles, 
that contain neurotransmitters which are important in the acute hypoxic ventilatory 
response (Gonzalez et al, 1994). Between adjacent type I cells, gap junctions allow 
the cells to communicate with each other, while tight junctions hold the cells in a 
glomerulus (Gonzalez et al., 1994; Kumar & Prabhakar, 2012).  Where type I cells 
are not joined with one another, type II, or sustentacular cells act like glia to hold the 
CB together. Type II cells account for less than 20% of the organ (De Kock, 1966), 
and unlike type I cells, type II cells are not excitable and do not form synapses with 
the CSN. The CB has a very high blood flow for its size and receives blood from the 
common carotid artery, namely the CB artery (Gonzalez et al, 1994). Blood is 
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drained from the organ via a venous plexus into the internal or external jugular 
veins (Kumar & Prabhakar, 2012). 
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Figure 1.  
A schematic showing the anatomy of the carotid body. A.) The carotid body sits at 
the bifurcation of the common carotid artery (CC) into the external carotid artery 
(EC) and the internal carotid artery (IC). The carotid sinus nerve receives afferents 
from type I cells in the carotid body. B.) The carotid bodies contain the excitable 
type I cells which form synapses with afferent carotid sinus nerves as well as glia-
like type II cells.  
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Figure 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
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The Carotid Body and the Control of Breathing 
  The CB has dual innervation. First, the afferent innervation for the CB is the 
CSN, a branch of cranial nerve IX, the glossopharyngeal nerve, whose cell bodies lie 
in the petrosal ganglion (Kumar & Prabhakar, 2012). The CSN communicates with 
type I cells of the CB and projects to the nucleus tractus solitarius (NTS) of the 
medulla (Finley and Katz, 1992). The second innervation to the CB is the 
ganglioglomular nerve carrying efferent sympathetic fibers from the superior 
cervical ganglion to the organ (Gerard & Billingsly, 1932). The ganglioglomular 
nerve innervates blood vessels in the CB to control blood flow to the organ 
(Gonzalez et al, 1994).  
 When blood is perfused through the organ, it is monitored by the 
chemosensitive type I cells. In response to stimuli, such as hypoxia, type I cells elicit 
an acute hypoxic response (Figure 2). First, K+ channels on the plasma membrane 
are inhibited (Lopez-Barneo et al, 1988) which results in a membrane 
depolarization. While the mechanism behind this inhibition is still debated, the K+ 
channels that play a major role in the hypoxic response in rats are the TASK-like 
“leak” channels and the BKCa channels (Buckler, 1997; Peers, 1990; Lopez-Barneo, 
2004). The membrane depolarization then causes voltage-gated Ca2+ channels 
(mainly L and P/Q type) to open, resulting in an increase of intracellular calcium 
([Ca2+]i) (Buckler & Vaughan-Jones, 1994). An increase in [Ca2+]i results in 
neurotransmitter release from type I cells and an increased firing rate of the CSN to 
the NTS of the medulla. From there, the NTS integrates information and interacts 
with the ventral breathing centers of the pons and medulla to produce an efferent 
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Figure 2. 
A schematic showing the acute hypoxic response in a type I carotid body cell. 
Adverse stimuli sensed by type I cells cause the following cascade of events: K+ 
channels are inhibited causing a membrane depolarization. This depolarization 
opens voltage-gated calcium channels, increasing the amount of intracellular 
calcium ([Ca2+]i). A rise in [Ca2+]i causes more neurotransmitters (NT vesicles) to be 
released onto the carotid sinus nerve (CSN), increasing the firing rate to the nucleus 
tractus solitarius (NTS), ultimately resulting in hyperventilation.  
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Figure 2.  
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response through the phrenic nerve and other ventilatory and cardiovascular 
reflexes. These reflexes ultimately increase O2 levels in the blood back to 
homeostatic levels (Teppema & Dahan, 2010; Gonzalez et al, 1995). 
 
Neurotransmitters Released by Type I Carotid Body Cells 
 The rise in [Ca2+]i causes the release of many neurotransmitters into the 
synaptic cleft between the type I cell and the CSN. The neurotransmitters can then 
act presynaptically (in a paracrine or an autocrine fashion) onto type I cells or 
postsynaptically on the CSN. The interplay between inhibitory and excitatory 
neurotransmitters determines the CB’s effect on the CSN.  
 
Acetylcholine & ATP 
 Acetylcholine (ACh) was identified as the first possible transmitter in the CB 
(Schweitzer & Wright, 1938). Along with ACh, the enzymes to synthesize and 
degrade ACh, choline acetyltransferase and acetylcholinesterase, respectively, are 
also found in the rat CB type I cells (Nurse, 1987). Once released from a type I cell, 
ACh can activate two different cholinergic receptors: nicotinic and muscarinic ACh 
receptors, which are both found presynaptically on type I cells and postsynaptically 
on the CSN (Wyatt & Peers, 1993; Shirahata et al, 2007). ACh is inhibitory via the 
muscarinic receptors and excitatory via the nicotinic receptors. 
The role of ACh in chemotransduction has been debated due to the findings 
that when cholinergic receptors are blocked, the afferent nerves still depolarize 
during a hypoxic stimulus (Zhang et al, 2000). It was discovered that a second 
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neurotransmitter, adenosine triphosphate (ATP), is co-released from type I cells 
with ACh (Zhang et al, 2000). ATP binds to P2X receptors located on the CSN and 
together, ACh and ATP are the main excitatory neurotransmitters released from 
type I cells (Zhang et al, 2000). It is important to note that ATP can act inhibitory 
because it also binds to P2Y receptors on type I and type II cells, which may act as a 
protective negative feedback mechanism (Xu et al, 2003; Xu et al, 2005). 
 
Dopamine 
 Dopamine (DA) is the main catecholamine found in the dense core vesicles of 
type I cells of rats (Vicario et al, 2000). DA is made by an enzyme typical of type I 
cells, tyrosine hydroxylase (TH), which converts tyrosine to DA. DA binds to D2 
receptors present on both the CB and the CSN (Lazarov et al, 2009; Dinger et al, 
1981; Mir et al, 1984). DA is typically an inhibitory monoamine in most mammals 
(Docherty & McQueen, 1978), but has been found to have excitatory effects in the 
rabbit CB (Gonzalez et al, 1994). More recently, DA has been thought of more as a 
neuromodulator. Under short-term (Wakai et al, 2010) and chronic (Wang & 
Bisgard, 2002) hypoxia, TH levels increase. The increased DA produced and 
ultimately released may act presynaptically to prevent intense hyperventilation. 
 
Enkephalins 
 Opioid peptides are classified into three categories: endorphins, dynorphins, 
and enkephalins. Met- and leu-enkephalin are predominately found as their 
precursor, proenkephalin A, in the CB (Gonzalez et al, 1994; Gonzalez-Guerrero et al, 
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1993a,b). Leu-enkephalin (LET) expresses an inhibitory effect on the pre-Bötzinger 
complex and the ventrolateral part of the NTS resulting in decreased respiratory 
rate (Inyushkin, 2007). Further, Gonzalez-Guerrero et al showed that at the level of 
the CB, the opioid peptides leu- and met-enkephalin are co-released with DA from 
type I cells (1993a,b). The co-release of DA and opioid peptides from the same 
dense-core vesicles could explain the dramatic decrease in respiration due to the 
inhibitory signal from type I cells to the postsynaptic CSN, as well as the protective 
feedback mechanism on the presynaptic type I cell itself. 
 
CLASSIFICATION OF OPIOID RECEPTORS 
 The discovery of opioid receptors was unique because the receptor was 
identified before the endogenous ligand was known (Pasternak, 2013). Martin was 
the first to suggest the presence of multiple types of receptors, and proposed 
morphine receptors, which are now known as the mu (μ) opioid receptors, and 
nalorphine receptors, now classified as kappa (κ) opioid receptors (Martin, 1967). A 
decade later, Kosterlitz classified the delta (δ) opioid receptor through the use of 
their endogenous ligand enkephalins (Lord et al, 1977). Other types of opioid 
receptors, such as the sigma opioid receptor and the opioid receptor like-1, have 
been categorized, but little is known about their functions or whether they are true 
opioid receptors (Al-Hasani & Bruchas, 2011). For this thesis, only the well-
understood μ, δ, κ opioid receptors will be examined. 
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Mu Opioid Receptors 
 The μ opioid receptors are the most studied opioid receptor due to their role 
in analgesia with their highly selective agonist morphine (Pradhan et al, 2012). 
Along with pain suppression, μ opioid receptor agonists can cause desired effects 
such as euphoria, anti-diarrhea, cough suppression, and undesirable effects like 
respiratory depression, constipation, vomiting, and dependence (Kelly, 2013).  
 The μ opioid receptors differ from the κ and δ opioid receptors in terms of 
exons. All three opioid receptors have seven transmembrane domains that include 
the first exon encoding the N-terminus and the first transmembrane domain in 
addition to a second and third exon, which each encode an additional three 
transmembrane domains. However, the μ opioid receptors have a fourth exon 
encoding 12 amino acids at the end of the C-terminus (Pasternak, 2013).  
 
Kappa Opioid Receptors 
 κ opioid receptor activation is involved in gut motility, feeding, mood, and 
diuresis (Pradhan et al, 2012). In contrast to the other two types of opioid receptors, 
the antagonists specific for κ opioid receptor, like norbinaltorphimine, have effects 
that last up to several weeks, in contrast to naloxone, an antagonist for all three 
types of receptors, which only has effects for a few hours (Pradhan et al, 2012).  
 
Delta Opioid Receptors 
 The δ opioid receptors have been linked to neuroprotection and 
cardioprotection when activated by their selective agonists (Feng et al, 2012). 
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Interestingly, stimulation of δ opioid receptors by JNJ-20788560 did not result in 
the adverse effects associated with the other opioid receptors, such as respiratory 
depression, constipation, and dependence (Codd et al, 2009). The endogenous 
ligands for the δ opioid receptors are enkephalins, which have been found in the CB 
of rabbits (Gonzalez et al, 1993b) and have been noted to depress chemosensory 
discharge from the CSN (Kirby & McQueen, 1986). 
 
Opioid Receptors: Gi Protein Linked  
All three families of opioid receptors are seven transmembrane G protein-
coupled receptors that activate inhibitory G proteins (Gi) (Al-Hasani & Bruchas, 
2011). Upon activation by a selective agonist, the Gαi and Gβγ subunits dissociate and 
act on various intracellular pathways. Most notably, opioid receptor activation has 
the ability to modulate ion channels.  
After opioid receptor activation and G protein dissociation (Figure 3), the Gβγ 
subunit binds to voltage-gated Ca2+ channels (VGCC) and inhibits calcium influx 
decreasing the amount of [Ca2+]i. (Al-Hasani & Bruchas, 2011). This decreased 
amount of [Ca2+]i then has the ability to affect downstream Ca2+—dependent cellular 
pathways, such as neurotransmitter release.  
Activation of opioid receptors also alters K+ channel conductance as a means 
to reduce cellular excitability and inhibit neurotransmitter release. As the Gαi 
subunit dissociates and binds to K+ channels, the increase in K+ conductance causes 
the cell to hyperpolarize ultimately inhibiting downstream neurotransmitter release 
(Satoh & Minami, 1995; Al-Hasani & Bruchas, 2011). 
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Additionally, the Gβγ subunit directly interacts with the members of the 
SNARE complex downstream of VGCCs through an independent mechanism (Figure 
4). The Gβγ subunit has been shown to specifically affect SNAP25 and syntaxin1A 
which can ultimately decrease the amount of neurotransmitter released from the 
type I cell. (Wells et al, 2012; Blackmer et al, 2005). 
The Gαi and the Gβγ subunits that alter the Ca2+ and K+ channel conductance 
are sensitive to pertussis toxin (PTX). PTX catalyzes the ADP-ribosylation of G 
proteins and by doing so prevents the agonist-induced dissociation of the proteins 
into active subunits (Katada et al, 1984; Holz et al, 1986).  
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Figure 3. 
A schematic showing the effect of opioid receptor activation on VCGGs. Upon 
activation by their selective agonists, all three families of opioid receptors (μ, κ, δ) 
respond by activating Gi proteins. The Gβγ subunit binds directly to VGCCs and 
inhibits Ca2+ influx resulting in a decrease of [Ca2+]i.  
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Figure 3. 
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Figure 4. 
A schematic showing the activation of an opioid Gβγ subunit binding directly to both 
VGCCs and the neurotransmitter (NT) synaptic machinery (i.e. SNARES and SNAP 
proteins) involved in secretory granule exocytosis.  
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Figure 4. 
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OPIATES AND BREATHING 
 The drive to breath is generated in the brainstem and is modulated by inputs 
from the cortex, central chemoreceptors located in the brainstem, and peripheral 
chemoreceptors, such as the CB and the aortic bodies. The main respiratory centers 
include the pre-Bötzinger complex, the retro-trapezoid and parafacial respiratory 
group, the locus coeruleus in the pons, and the NTS (Pattinson, 2008; Greer et al, 
1995; Han et al, 1997).  
It has been shown that there is a high concentration of opioid receptors in 
areas of the brain related to respiration (Mutolo et al, 2007; Mansour & Watson, 
1993). Activation of opioid receptors in these respiratory centers of the brain and 
brainstem affects ion channels through Gi proteins, which can alter the excitability 
of neurons and ultimately affect respiration patterns. At low doses, opioids change 
the respiratory patterns whereas at high doses, they reduce tidal volume (Lalley, 
2003). 
 Ballanyi et al proposed after a study in newborn mouse brainstem slices that 
the depression of breathing by opioids is caused by the postsynaptic K+ channel 
hyperpolarization of inspiratory neurons in the pre-Bötzinger complex (2010). On a 
bigger scale, opioids blunt respiratory responsiveness to CO2 and hypoxia, depress 
the rate and depth of breathing, increase upper airway resistance and reduce 
pulmonary compliance (Feng et al, 2012).  
Specifically, μ opioid receptor activation decreases respiratory rate and can 
lead to complete apnea upon overdose (Feng et al, 2012). The μ opioid receptor 
agonist, DAMGO caused a naloxone-reversible, dose-dependent decrease in the 
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frequency of respiratory rhythmic discharge when applied to the bathing solutions 
of the neonatal rat brainstem (Greer et al, 1995). Furthermore, the activation of μ 
opioid receptors in the NTS eliminated the hypoxic ventilatory response in rats 
(Zhang et al, 2011). Overall, these studies show that opioids can affect the acute 
hypoxic response and ultimately the respiration patterns in rodents via the central 
nervous system.  
The primary efferent nerve involved in respiration is the phrenic nerve. The 
phrenic nerve innervates the diaphragm muscle, the main muscle of inspiration. It 
has been shown that U50-488, a selective agonist for the κ opioid receptor, causes a 
dose-dependent reduction in phrenic nerve discharge when studied in decerebrated 
cats (Haji & Takeda, 2001).  
Activation of δ opioid receptors has a less pronounced effect on breathing. In 
vitro, the addition of [D-Pen2,5]enkephalin, a δ opioid receptor agonist, did not 
affect the respiratory burst frequency or the amplitude (Greer et al, 1995). However, 
it is important to note that no opioids lack respiratory side effects (Pattinson, 2008). 
Alternatively, in the peripheral nervous system, no opioid signaling research 
has been done on isolated type I CB cells; only whole CBs have been examined. In 
studies in which fentanyl was used with canine carotid bodies, it was found that 
carotid chemoreception increases the respiratory drive while fentanyl, a common 
opioid, decreases the respiratory drive (Mayer et al, 1989). It has been shown that 
activation of opioid receptors in the peripheral nervous system inhibits the acute 
hypoxic response, but the mechanism is still not known (Kirby & McQueen, 1986).   
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HYPOTHESIS  
 It has been demonstrated that activation of opioid receptors in the CBs can 
inhibit the acute hypoxic response (Kirby & McQueen, 1986); however, the 
mechanism behind this inhibition is not yet understood. Activation of opioid 
receptors alters the mechanisms by which neurotransmitters are released by 
affecting ion channels directly. This thesis will test the hypothesis that activation of 
opioid receptors on the type I cells of the rat CB may inhibit the influx of Ca2+ via Gi-
protein coupled receptors, reducing neurotransmitter release, decreasing the firing 
rate of the CSN and ultimately inhibiting the acute hypoxic response. 
 
SUMMARY 
  The CBs are the primary peripheral chemoreceptors located at the 
bifurcation of the common carotid arteries. In response to adverse changes in blood 
gases, such as an increase in CO2 or a decrease in O2, the chemosensitive type I cells 
depolarize and release neurotransmitters onto the CSN. The CSN then relays the 
information via the glossopharyngeal nerve to the NTS in the brainstem, which 
ultimately causes hyperventilation to restore homeostasis.  
 To test the hypothesis of this thesis, immunofluorescence can identify which 
opioid receptors are present on rat carotid body type I cells. Next, calcium imaging 
can examine the effects of receptor activation by their selective agonists. Finally, 
calcium imaging can also help characterize the effects seen to identify the 
mechanism by which opioids inhibit the CB-driven acute hypoxic response in the 
peripheral nervous system. 
 22 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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All studies described in this paper were performed in accordance with 
protocols approved by the Wright State University Institutional Laboratory Animal 
Care and Use Committee (IACUC). These protocols are in accordance with the 
National Institute of Health guide for the care and use of laboratory animals (NIH 
publications No. 80-23) revised 1996.  
 
DISSECTION AND DISSOCIATION OF NEONATAL RAT CAROTID BODY TYPE I 
CELLS 
 On experimental days, three or four neonatal Sprague Dawley rats (aged 10-
20 days) were placed in an induction chamber supplied with 4.5% isofluorane and 
oxygen to initially anesthetize the animal. When the animal reached 
unconsciousness, it was transferred from the induction chamber to a nose cone 
supplying the same anesthetic gas. To ensure that the animal was completely 
anesthetized, the foot pinch withdrawal reflex was tested. Only after no reflex was 
seen were the following experimental procedures taken: The rat’s forelegs were 
taped down to reduce any movement and an incision was made along the rat’s 
sternum to expose underlying subcutaneous fascia. This fascia, the salivary glands, 
and the skeletal muscles lateral to the trachea were removed using very fine forceps 
(Moria, Fine Science Tools, USA), which exposed the common carotid artery while 
being careful not to cut or damage any adjacent blood vessels. 
 The remainder of the dissection was done under a low magnification 
microscope (Omâno, Japan). Once the common carotid artery became visible, any 
remaining fat and fascia was removed to observe the bifurcation of the common 
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carotid into the internal and external carotid arteries. After removal of the 
glossopharyngeal nerve and the reflection of the occipital artery, the carotid body, 
usually adhered to the internal carotid artery by connective tissue, became visible in 
the bifurcation. The organ was then carefully pinched off using forceps and placed 
directly into ice cold, oxygenated, Dulbecco’s phosphate buffered saline (DPBS) 
without Ca2+ or Mg2+ (Sigma).  Following the extraction of the carotid body, the rats 
were euthanized via decapitation while still deeply anesthetized and disposed of in 
accordance with Lab Animal Research specifications. The six to eight carotid bodies 
were then returned to the lab and cleaned of any remaining connective tissue under 
the dissection Omâno microscope.  
 The cleaned carotid bodies were then transferred to a digestive enzyme 
solution (0.4 mg/ml collagenase type I, 249 u/mg (Worthington Biochemical 
Corporation), 0.2 mg/ml trypsin type I, 10,000 BAEE u mg-1 (Sigma) in DPBS with 
low CaCl2 (86 μM) and MgCl2 (350 μM)) and incubated for 20 minutes at 37°C to 
dissolve the connective tissue holding the carotid body together.  Then, the carotid 
bodies were teased apart and incubated for another 7 minutes at 37°C. The tissue 
was removed from the Petri dish and transferred to a test tube using a fire polished, 
silanized (Sigmacote, Sigma) Pasteur pipette where it was centrifuged at 110g for 5 
minutes. The cells were resuspended in tissue culture medium, (Ham’s F12 (Sigma) 
supplemented with 10% heat inactivated fetal bovine serum (Biowest)) triturated, 
and centrifuged for another 5 minutes at 110g. Finally, the cells were resuspended 
in tissue culture medium and plated onto 22mm2 poly-D-lysine (Sigma) coated 
coverslips (Fisher Scientific) for immunofluorescence or 15mm diameter   
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poly-D-lysine coated coverslips (Warner Instruments) for Ca2+ imaging. Coverslips 
were placed in 35mm Petri dishes and maintained at 37°C in a humidified, 5% 
CO2/air incubator for 2 hours to allow the cells to adhere to the coverslips.  
 
IMMUNOFLUORESCENCE   
 Coverslips with adhered type I cells were fixed by immersion in methanol at     
-20°C for 15 minutes. Cells were then washed 3 x 5 minutes with a permeabilization 
and blocking solution (0.3% triton X-100 and 1% bovine serum albumin in 
phosphate buffered saline (PBS)) which allowed antibodies to enter the cell and 
limited unspecific binding of the anti-opioid receptor antibodies to reduce 
background or nonspecific staining. Specific primary antibodies were used to 
identify the different three opioid receptors while an anti-TH antibody identified the 
cells as type I cells.  
The anti-δ opioid and the anti-μ opioid receptor 1° antibodies (Santa Cruz 
Biotechnology: sc-9111, sc-15310) were rabbit polyclonal antibodies diluted to 
1:200 with the blocking solution, whereas the anti-κ opioid receptor 1° antibody 
(USBiological, O7030-31A) was a rabbit polyclonal antibody diluted to 1:1000 with 
the blocking solution. All primary antibodies were added to the appropriate 
coverslips with the anti-TH 1° antibody (Sigma) at a dilution of 1:1000 in blocking 
solution and incubated at 4°C for 16 hours. 
Following the incubation with the 1° antibodies, coverslips were washed 2 x 
10 minutes with the blocking solution and then incubated for 2 hours in the dark at 
room temperature with the 2° antibodies diluted to 1:200 with the blocking 
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solution. In the first set of experiments, the antibodies used were a Rhodamine Red-
X-conjugated AffiniPure donkey anti-sheep IgG 2° antibody which identified the TH 
and a Fluorescein (FITC)-conjugated AffiniPure donkey anti-rabbit IgG 2° antibody 
which marked the specific opioid receptors (Figure 5). Due to poor control 
experiments (Figure 9) in which no 1° antibodies were added to the coverslips and 
the 2° antibody for TH was non-specifically binding, a second set of experiments 
were conducted with a Rhodamine Red-X-conjugated AffiniPure donkey anti-rabbit 
IgG 2° antibody marking the opioid receptors and a Fluorescein (FITC)-conjugated 
donkey anti-mouse IgG 2° antibody identification of TH (Figure 6). All 2° antibodies 
were supplied by Jackson Immunoresearch. The δ opioid receptors have previously 
been shown to be present in dorsal root ganglion cells (Zhang & Bao, 2012); 
therefore, a positive control experiment was used to test the validity of the anti-δ 
opioid receptor 1° antibodies (Figure 7). 
Immunofluorescence images were acquired using a DeltaVision microscope 
system (Applied Precision) on an inverted Olympus IX71 microscope with an oil 
immersion, x63 magnification, 1.4 n.a. objective and Coolsnap HQ CCD camera 
(Photometrics). Images were acquired with settings for a 768 x768 image size, 
RDTRPE 617/73 nm emission and 555/28 nm excitation, FITC 528/38 nm 
emission and 490/20 nm excitation, and a DAPI 457/50 nm emission and 360/40 
nm excitation.  Multiple Z-sections were taken through each cell and the images 
were deconvolved through the Softworx software to reassigned out-of-focus light 
(Applied Precision).  
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Figure 5.  Opioid receptor staining in isolated carotid body type I cells 
using double immunofluorescence. In the first set of experiments, the 1° antibody 
identified the receptors while the 2° antibodies, which are fluorescent, stained 
tyrosine hydroxylase (TH) red and the opioid receptors (OR) green. The antibodies 
responsible for identifying and staining the receptors are listed. 
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Figure 5. 
 
Antibody Target Fluorochrome Color 
1° rabbit anti-rat μ, δ, κ opioid 
receptors 
Fluorescein 
(FITC) 
Green 
2° donkey anti-rabbit 
1° sheep anti-rat Tyrosine 
Hydroxylase 
Rhodamine Red 
2° donkey anti-sheep 
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Figure 6.  Opioid receptor staining in isolated carotid body type I cells 
using double immunofluorescence. In the second set of experiments, the same 1° 
antibodies identified the receptors, but the new 2° antibodies stained the tyrosine 
hydroxylase (TH) green and the opioid receptors (OR) red. The 1° and 2° antibodies 
responsible are listed.   
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Figure 6. 
 
Antibody Target Fluorochrome Color 
1° rabbit anti-rat μ, δ, κ opioid 
receptors 
Rhodamine Red 
2° donkey anti-rabbit 
1° mouse anti-rat Tyrosine 
Hydroxylase 
Fluorescein 
(FITC) 
Green 
2° donkey anti-mouse 
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Figure 7.  Delta opioid receptor staining in dorsal root ganglion (DRG) 
cells. The 1° and 2° antibodies used to identify and stain the δ opioid receptors (OR) 
green are listed.  
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Figure 7. 
 
Antibody Target Fluorochrome Color 
1° rabbit anti-rat δ opioid receptors Fluorescein 
(FITC) 
Green 
2° donkey anti-rabbit 
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FURA-2AM 
 Fura-2AM is a molecular probe used to determine intracellular calcium 
concentrations through fluorescence (Figure 8). The acetoxymethyl ester portion of 
the probe allows the molecule to diffuse through the plasma membrane of the cell, 
which avoids using more invasive techniques for loading. Once the probe is inside 
the cell, the cell’s esterases cleave off the acetoxymethyl portion, leaving the cell-
impermeant fluorescent indicator behind. Upon binding Ca2+, Fura-2 exhibits an 
absorption shift that can be observed by scanning the excitation spectrum between 
300 and 400 nm, while monitoring the emission at ~510 nm (invitrogen.com).  In 
these imaging experiments, the Fura-2 was excited by exposure to both 340 nm and 
380 nm wavelengths of light while monitoring emissions at 510 nm. Calculations 
made by looking at the ratios of emitted light evoked by 340 nm/380 nm excitation 
allowed us to determine the intracellular concentration of calcium at specific 
moments in time due to this formula: 
  [Ca2+] = Kd (Sf2/Sb2)(Rexp-Rmin/Rmax-Rexp) 
 Kd = 224 x 10-9 M     Rexp = measured experimental ratio 
Sf2 = intensity 380 nm Ca2+ free   Rmax = Ca2+ saturated ratio 
Sb2 = intensity 380 nm Ca2+ saturated   Rmin = 0 Ca2+ ratio 
 
 Thus, the measured experimental ratio is directly proportional to the calcium 
concentration in the cell and can be calculated by calibrating the system using a 0 
nm Ca2+ solution and a saturating Ca2+ solution which is typically 5 mM. All 
fluorescent values in this research are given as ratio units rather than Ca2+ 
concentrations because previous students in the Wyatt laboratory have not been 
able to acquire satisfactory Sb2 readings.  Furthermore, by using two different 
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wavelengths of light to measure concentration, variables such as dye bleaching and 
cell thickness can be eliminated which prevents unwanted artifact.  
 
CALCIUM IMAGING 
 Cells were visualized with a Nikon Eclipse TE2000U inverted microscope 
with a CFI super fluor x40 oil immersion objective. Fura-2 was excited with 50 msec 
exposures to 340 nm and 380 nm light at 0.2 – 0.5 Hz using a Lambda 10 – 3 filter 
wheel (Sutter) and emitted fluorescence measured at 510 nm using a CoolSNAP 
HQ2 CCD camera. Light was provided by a Lambda-LS xenon arc lamp (175 watt, 
Sutter). Because of the high wattage of this lamp, the light first passed through 
neutral density filters of 0.7 optical densities (Chroma, USA) before reaching the 
isolated cells to prevent any cell photodamage.  
 Data acquisition and analysis was completed using Metafluor 7.1.2 imaging 
software (Molecular Devices). The 340/380 ratio images were generated online 
after regions of interest were placed around cells to show changes in the 
fluorescence ratio over time.  
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Figure 8. Fluorescence emission of Fura-2 at differing wavelengths. This graph 
shows the varying fluorescence of Fura-2 due to excitation wavelength and 
intracellular free-calcium concentration. The dye was excited at wavelengths listed 
along the x-axis. When the intracellular calcium level is zero, the fluorescence 
intensity at 340 nm is less than the intensity at 380 nm when viewed at 510 nm. As 
the free calcium level increases, the fluorescence intensity at 340 increases as the 
fluorescence intensity at 380 nm decreases as viewed at 510 nm. Image from 
Molecular Probes.  
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Figure 8. 
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PERFUSION OF ISOLATED TYPE I CAROTID BODY CELLS 
 Isolated cells, plated on 15 mm round coverslips, were placed into the 
perfusion chamber and washed with HEPES buffered saline solution (NaCl 140mM, 
KCl 4.5mM, CalCl2 2.5mM, MgCl2 1mM, Glucose 11mM, HEPES 10mM; pH to 7.57 
with NaOH) for approximately 5 minutes. Temperatures were maintained between 
34°-36°, keeping the final pH 7.4, by passing solutions through an in-line heater (SH-
27F, Warner Instruments, USA) which was controlled by feedback to an automatic 
temperature controller (TC-344B, Warner Instruments, USA).  
 The dissociation process yields predominately individual, isolated type I 
cells, with sporadic clusters of cells. Regions of interest (ROI) were drawn over cells 
using the Metafluor software and the calcium signal was taken within the ROI. 
Changes in the calcium signal were measured from the baseline to the peak 
response during exposure. Only cells that responded to a 80mM K+ HEPES stimulus 
(NaCl 64.5mM, KCl 80mM, CalCl2 2.5mM, MgCl2 1mM, Glucose 11mM, HEPES 10mM; 
pH to 7.57 with KOH; 80mM KCl was used to evoke maximal Ca2+ influx) with a 
rapid increase in fluorescence ratio, recovered back to the predetermined baseline, 
showed no spontaneous Ca2+ spiking, and had steady baselines were used in this 
study. The complete recovery from the K+ stimulus had to occur to ensure that the 
Ca2+ handling properties of the type I cell were healthy. Recording from individual 
cells represents n=1. Compounds (Table 1) were only applied to a coverslip once to 
avoid the possibility of desensitization or sensitization.  
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 Solution changes occurred by switching the solution inflow to a chamber 
containing the solution of choice. The solutions were perfused by gravity and the 
exchange was usually complete within 15 seconds. 
 
STATISTICAL SIGNIFICANCE 
 Data are presented as means ± standard error of the mean. Differences 
between individual means were determined by an unpaired student’s t-test. A value 
of p<0.05 was taken to indicate statistical significance.  
 
CHEMICALS 
 The drugs used in this research are included in Table 1.  
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Table 1. 
Compound Target Source 
[D-Ala2, N-Me-Phe4, Gly5-ol]-enkephalin acetate 
salt 
(DAMGO) 
μ opioid 
receptor 
Sigma-
Aldrich 
U50-488 hydrochloride κ opioid 
receptor 
Sigma-
Aldrich 
Pertussis Toxin Gi protein Sigma-
Aldrich 
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IMMUNOFLUORESCENCE  
 Immunofluorescence was used to identify which of the opioid receptors (μ, κ, 
or δ) were present on the membranes of rat CB cells type I cells. TH identified the 
cells as type I cells while DAPI (blue) identified the nucleus. Control experiments 
were only treated with the 2° antibodies; no 1° antibodies were applied to the 
control coverslips. Images were acquired using a DeltaVision microscope and each 
image represents an example z-section through the cell. Results are described 
qualitatively rather than quantitatively.  
 
Type I Cells 
 From the images, staining can be seen for both the μ opioid receptors and the 
κ opioid receptors but little to no staining is seen for δ opioid receptors (Figure 9). 
The staining for the μ and κ opioid receptors is targeted to the cytoplasm and cell 
membrane whereas the majority of δ staining is found in the nucleus, which may be 
nonspecific. However, in this set of experiments, our control images showed 
nonselective red staining of the 2° antibody for TH. This is abnormal because the 
controls were not treated with the 1° antibodies. Because of this, a second 
experiment was performed with a new 1° antibody for TH and new 2° antibodies for 
both the opioid receptors and for TH. 
 In the second set of experiments, there was staining for both the μ and the κ 
opioid receptors, but very faint staining was seen for the δ opioid receptors (Figure 
10).  The brightest staining for the μ and κ opioid receptors was in the cytoplasm 
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and on the cell membrane. The control images were clear of any nonselective 2° 
antibody staining showing that our 2° antibody was more selective and only binding 
to our 1° antibodies when present. 
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Figure 9. Opioid receptor staining in isolated rat CB type I cells using double 
immunofluorescence. The 2° antibodies stained the opioid receptors green and 
tyrosine hydroxylase (TH) red while DAPI stained the nucleus blue. Staining is 
present for μ and κ opioid receptors and is not present for δ opioid receptors. 
Control image shows nonselective staining for the TH 2° antibody even when the 1° 
antibody was absent. All images are 15 microns.  
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Figure 9. 
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Figure 10. Opioid receptor staining in isolated rat CB type I cells using double 
immunofluorescence. The receptors, tyrosine hydroxylase (TH), and the nucleus are 
all shown in 16-bit greyscale. The 2° antibodies stained the opioid receptors red and 
TH green while DAPI stained the nucleus blue in the merged images. Staining is 
present for μ and κ opioid receptors and is not present for δ opioid receptors. TH is 
seen throughout the cytoplasm of μ, κ, and δ stained cells. Control images show 
absence of 2° antibody staining when 1° antibodies were absent. Images for the 
controls, μ, and κ are scaled to 15 microns. Images for δ staining are scaled to 20 
microns.  
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Figure 10. 
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Dorsal Root Ganglion Cells 
 To test the integrity of the 1° antibody for the δ opioid receptor, a positive 
control experiment was performed on rat dorsal root ganglion (DRG) cells. DRG cells 
were chosen because δ opioid receptors have previously been shown in this cell 
type (Zhang & Bao, 2012). From these images (Figure 11), it can be concluded that 
our δ 1° antibody worked to identify the δ opioid receptor in the previous 
experiment. The δ opioid receptor has minimal staining in the nucleus, but can be 
seen with very pronounced staining in the cell membrane and cytoplasm of the DRG 
cell. The control DRG cell was not treated with 1° antibodies and is clear of any 
nonselective 2° antibody staining. 
 From these immunohistochemistry experiments, it can be concluded that μ 
and κ opioid receptors are present on rat CB type I cells whereas δ opioid receptors 
are not present. This is the first classification of opioid receptors on rat CB type I 
cells.  
 
CALCIUM IMAGING  
 A concentration of 80mM K+ was applied to the cells to ensure that they were 
viable. Only cells that responded to the stimulus with a rapid and reversible rise in 
[Ca2+]i were chosen. Cells were then exposed to the agonist (DAMGO for the μ opioid 
receptor; U50-488 for the κ opioid receptor) for a minimum of 4 minutes before a 
80mM K+ stimulus was applied in the presence of the agonist. Finally, a third 80mM 
K+ stimulus was applied to the cell to ensure that the cell was still viable. The control 
cells did not have an agonist applied.  
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Figure 11. Opioid receptor staining in rat DRG cells. The 2° antibody stained the 
opioid receptors green while DAPI stained the nucleus blue. The δ opioid receptors 
are targeted to the cytoplasm and cell membrane. Bright, punctate δ opioid receptor 
staining showed that the 1° antibody is binding to the receptors which then can 
confirm that δ opioid receptors are absent from type I rat CB cells. Images are scaled 
to 15 microns. 
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Figure 11. 
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Controls 
 Isolated rat CB type I cells experienced a reduction in voltage-gated Ca2+ 
influx upon repetitive stimulation by the 80mM K+ stimulus. Among 12 cells, there 
was an average reduction of 12.99 ± 1.46% between the first and second K+ 
responses. Therefore, to analyze the effect of an agonist, the percent reduction in the 
controls was compared to the percent inhibition in the presence of the agonist, 
using an unpaired student’s t-test (Figure 12). 
 
Effect of 1μM DAMGO 
 DAMGO was chosen as the μ opioid receptor agonist because of proven 
selectivity in isolated neuronal cells (Greer et al, 1995; Kelly, 2013; Handa et al, 
1981). In the presence of 1μM DAMGO (N=7), there was an average inhibition of 
voltage-gated Ca2+ influx of 9.59 ± 2.77% between the first and second K+ responses, 
with the second response in the presence of DAMGO (Figure 13). Compared to the 
controls, 1μM DAMGO does not have a statistically significant (p<0.25) effect on the 
voltage-gated Ca2+ influx. 
 
Effect of 1μM U50-488 
 U50-488 was chosen as the κ opioid receptor agonist because of its 
selectivity toward the κ opioid receptor and its poor affinity for the μ opioid 
receptor (Clark & Pasternak, 1988; Dayanithini et al, 1992). In the presence of 1μM 
U50-488 (N=7), there was an average inhibition of voltage-gated Ca2+ influx of 14.04 
± 1.89% between the first and second K+ responses, with the second response in the 
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presence of U50-488 (Figure 13). Compared to the controls, 1μM U50-488 does not 
have a statistically significant (p<0.67) effect on the voltage-gated Ca2+ influx. 
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Figure 12.  Analyzing Ca2+ imaging results. A.) The reduction in the 
controls between the first two K+ responses as indicated by the black arrow. B.) 
Representation of the inhibition that occurred (black arrow) between the first K+ 
response and the second K+ spike in the presence of the agonist, as noted by the blue 
box. To analyze the results, the average reduction seen in the controls (A) was 
compared to the average inhibition seen in the presence of the agonist (B) using an 
unpaired students t-test with a p<0.05. 
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Figure 12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A. B. 
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Figure 13. Effects of 1μM DAMGO and 1μM U50-488 on isolated type I CB cell 
Fura-2 Fluorescence ratios. The control example cell (A) shows the slight decrease 
in 80mM K+-evoked Ca2+ entry after repeated applications of K+ over time (N=12). 
Neither the example cell exposed to 1μM DAMGO (N=7), as seen by the red box (B), 
nor the example cell exposed to 1μM U50-488 (N=7), as seen by the green box (C), 
show a significant inhibition of 80mM K+-evoked Ca2+ entry into the cell. The 
histogram (D) shows the average percent inhibitions for the controls (12.99± 
1.34%), 1μM DAMGO (9.59± 2.76%) and 1μM U50-488 (14.04 ± 1.88%). Scale bar 
indicates 2 minutes.  
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Figure 13.  
 
 
 
 
 
 
 
 
 
 
 
Effect of 10μM DAMGO 
A. B. 
C. D. 
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 With concentrations of 1μM having no statistically significant effect on 
voltage-gated Ca2+ influx, the concentrations of the agonists were increased to 
10μM. This is the maximal concentration that can be used to keep selectivity among 
the individual receptors. At a concentration of 10μM (Figure 14), DAMGO had an 
average percent inhibition of voltage-gated Ca2+ influx of 26.23 ± 2.92% (N=11). 
Compared to the controls, 10μM DAMGO had a statistically significant (p<0.0004) 
effect on the voltage-gated Ca2+ influx. 
 
Effect of 10μM U50-488 
At a concentration of 10μM, U50-488 elicited an average percent inhibition of 
voltage-gated Ca2+ influx of 22.22 ± 2.47% (N=11). Compared to the controls, 10μM 
U50-488 had a statistically significant (p<0.003) effect on the voltage-gated Ca2+ 
influx (Figure 14). 
 
PERTUSSIS TOXIN  
 Pertussis toxin (PTX) was used as a Gi protein inhibitor to confirm the 
pathway hypothesized in this thesis (Mangmool & Kurose, 2011; Holz et al, 1986). 
PTX catalyzes the ADP-ribosylation of G proteins and by doing so prevents the 
agonist-induced dissociation of the proteins into active subunits (Katada et al, 1984; 
Holz et al, 1986). PTX-sensitive G proteins typically inhibit high-threshold Ca2+ 
channels of the N- and P/Q-types, of which P/Q-types are located on the CB (Buckler 
& Vaughan-Jones, 1994; Hille, 1994). Cells were incubated for 3 hours in the 
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presence of 150 ng/ml of PTX and Ca2+ imaging examined the effects on voltage-
gated Ca2+ influx (Holz et al, 1986). 
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Figure 14.  Effects of 10μM DAMGO and 10μM U50-488 on type I CB cell Fura-2 
Fluorescence ratios. The control example cell (A) shows the slight decrease in 80mM 
K+-evoked Ca2+ entry after repeated applications of K+ over time (N=12). The 
example cell exposed to 10μM DAMGO (N=11), as seen by the red box (B), shows a 
statistically significant inhibition of 80mM K+-evoked Ca2+ entry into the cell 
(p<0.0004). The experimental example cell exposed to 10μM U50-488 (N=8), as 
seen by the green box (C), shows a statistically significant inhibition of 80mM K+-
evoked Ca2+ entry into the cell (p<0.003). The histogram (D) shows the average 
percent inhibitions for the controls (12.99± 1.34%), 10μM DAMGO (26.43± 2.92%) 
and 10μM U50-488 (22.22 ± 2.47%). Scale bar indicates 2 minutes. 
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Figure 14.  
 
 
 
 
 
 
 
 
 
 
 
Controls in the presence of PTX 
A. B. 
C. D. 
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 The first K+ response was not statistically different from the first K+ response 
of the controls that were not incubated with PTX (p<0.53). This was tested to ensure 
that PTX did not affect the Ca2+ handling properties or excitability of the type I CB 
cells. The controls after the incubation with PTX (N=7) had an average inhibition of 
11.22 ± 2.66% (Figure 15). 
 
Effect of 10μM DAMGO with PTX incubation 
 After incubating with PTX, the average inhibition of the voltage-gated Ca2+ 
influx by 10μM DAMGO (N=12) was 18.95 ± 3.02% (Figure 15). Compared to the 
controls also incubated with PTX, the effect of 10μM DAMGO on the response to K+ 
was not statistically significant after a 3 hour incubation with 150 ng/ml of PTX 
(p<0.1).  
 
Effect of 10μM U50-488 with PTX incubation 
After incubating with PTX, the average inhibition of the voltage-gated Ca2+ 
influx by 10μM U50-488 (N=7) was 17.47 ± 1.81% (Figure 15). Compared to the 
controls also incubated with PTX, the effect of 10μM U50-488 on the response to K+ 
was not statistically significant after a 3 hour incubation with 150 ng/ml of PTX 
(p<0.08). 
 
 
Figure 15. Effects of 10μM DAMGO and 10μM U50-488 on type I CB cell Fura-2 
Fluorescence ratios after a 3 hour incubation with PTX. All cells (including controls) 
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were treated with a 3 hour incubation in 150 ng/ml of PTX. The control example cell 
(A) shows the slight decrease (11.21 ± 2.66%) in 80mM K+-evoked Ca2+ entry after 
repeated applications of K+ over time (N=7). Neither the example cell exposed to 
10μM DAMGO (N=12), as seen by the red box (B), nor the example cell exposed to 
10μM U50-488 (N=7), as seen by the green box (C), show a statistically significant 
inhibition of 80mM K+-evoked Ca2+ entry into the cell. The histogram (D) shows the 
average percent inhibitions for the controls (11.21 ± 2.66%) 10μM DAMGO (18.95 ± 
3.02%) and 10μM U50-488 (17.47 ± 1.81%). Scale bar indicates 2 minutes. 
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Figure 15.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
A. B. 
C. D. 
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RESULTS SUMMARY 
 Through immunohistochemistry, it was discovered that μ and κ opioid 
receptors were present on the rat type I CB cells, whereas δ opioid receptors were 
not present. When tested, with their selective agonist at 1μM concentrations, both 
DAMGO for the μ opioid receptor, and U50-488 for the κ opioid receptor, were not 
statistically significant at inhibiting voltage-gated Ca2+ entry into the type I cell. 
However, at 10μM, DAMGO and U50-488 were both statistically significantly at 
inhibiting voltage-gated Ca2+ entry into the type I cell.  
Following a 3 hour incubation in PTX, a Gi protein inhibitor, neither 10μM 
DAMGO nor 10μM U50-488 were statistically significant when it came to inhibiting 
voltage-gated Ca2+ entry into the type I cell. Therefore, it can be concluded that the 
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opioid receptor-mediated inhibition of voltage-gated Ca2+ influx occurs via PTX-
sensitive Gi proteins. 
These data support the hypothesis and show that when activated by agonists, 
the μ and κ opioid receptors on type I CB cells activate Gi proteins which inhibit the 
influx of voltage-gated Ca2+, which could reduce neurotransmitter release, 
decreasing the firing rate to the CSN, and ultimately inhibiting the acute hypoxic 
response in the peripheral nervous system.  
 
FUTURE EXPERIMENTS 
 Although it has been concluded that the inhibition occurs via a PTX-sensitive 
Gi protein pathway, the inhibition is relatively small when compared to the 
concentrations of the agonists applied. Since it is no longer possible to increase the 
concentrations of our agonists without losing selectivity to their receptors, it is 
probable that the Gi proteins are working through other pathways to decrease the 
neurotransmitter release and thereby decrease the firing rate of the CSN. The Gβγ 
subunit binds to voltage-gated Ca2+ channels causing inhibition, but it has also been 
shown to directly bind to synaptic machinery (Figure 4) through a separate 
mechanism (Wells et al, 2012; Blackmer et al, 2005).  By affecting the SNARES and 
SNAP proteins that enable the neurotransmitters to be released from the cell, the 
Gβγ subunit could inhibit neurotransmitter release more directly and further inhibit 
the CSN firing leading to an inhibition of the acute hypoxic response.  
To examine if opioid receptors are coupled to the exocytotic machinery, a 
future experiment could be to measure neurotransmitter release at a constant level 
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of intracellular calcium (Figure 16). Man-Song-Hing et al used a similar technique to 
measure neurotransmitter release while clamping Ca2+ at a constant level in 
Helisoma neurons (1989), but it could be challenging to replicate these techniques 
in type I cells due to the difficultly in measuring neurotransmitters released from 
isolated type I CB cells. 
 Additionally, the experiments presented in this thesis were completed on 
samples of both male and female rats and no analysis was done comparing the 
effects of agonists based on gender because our data did not seem to conform to two 
main groups. However, it would be interesting to perform more experiments 
comparing the effects of agonists on voltage-gated Ca2+ influx in males to the effects 
in females due to the fact that female rat brains were less sensitive than male rat 
brains to the effects of κ opioid receptor agonist U50-488 (Russell et al, 2013).  
Figure 16.  Schematic showing a possible future experiment to test 
whether Gβγ subunits bind to synaptic machinery. To assess whether opioid 
receptors on type I CB cells are coupled to exocytotic machinery, intracellular 
calcium must be clamped at a constant level. This would allow the researcher to 
conclude that the Gβγ subunit was not only affecting the voltage-gated Ca2+ channels, 
but that it also was involved in altering the neurotransmitter release directly which 
could drastically inhibit the acute hypoxic response in the peripheral nervous 
system. 
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Figure 16. 
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Another possible thought would be to explore if opioid receptors were in the 
endothelium of the blood vessels supplying the CB and if activation of these opioid 
receptors had an effect on the acute hypoxic response. However, using a reverse 
transcriptase polymerase chain reaction and Southern blotting, it was shown that 
opioid expression was not found in the endothelium of rats (Wittert et al, 1996). 
 
CONCLUSIONS 
Type I CB cells sense changes in blood gases and release neurotransmitters 
that cause hyperventilation to restore homeostasis. Opiates blunt this acute hypoxic 
response, which can result in irregular breathing patterns. The purpose of this work 
was to identify the mechanism by which opioids affect breathing in the peripheral 
nervous system through the CB. The results indicate that at concentrations of 10μM, 
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DAMGO and U50-488 inhibit voltage-gated Ca2+ influx into the type I cells. This 
inhibition could lead to a reduced release of neurotransmitters, a reduced firing of 
the CSN, and ultimately an inhibition of the acute hypoxic response in the peripheral 
nervous system. Although other mechanisms play into the inhibition of the acute 
hypoxic response, it can be concluded from this work that the inhibition of voltage-
gated Ca2+ channels is a part of the overall effect. 
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